Search
R207910
New drug in clinical trials.
Indications:
- treatment of Mycobacterium tuberculosis
Mechanism of action:
1) inhibits ATP synthase
2) 10-fold greater bactericidal activity against M. tuberculosis than isoniazid or rifampin
Interactions
drug interactions
General
diarylquinolone
Properties
INHIBITS: F1F0 ATPase
Database Correlations
PUBCHEM correlations
References
- Journal Watch 25(4):31-32, 2005
Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM,
Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P,
de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C,
Lounis N, Jarlier V.
A diarylquinoline drug active on the ATP synthase of Mycobacterium
tuberculosis.
Science. 2005 Jan 14;307(5707):223-7. Epub 2004 Dec 09.
PMID: 15591164